MARKET

IMGN

IMGN

ImmunoGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.76
+0.24
+3.60%
Opening 10:12 06/24 EDT
OPEN
6.61
PREV CLOSE
6.52
HIGH
6.76
LOW
6.59
VOLUME
109.46K
TURNOVER
--
52 WEEK HIGH
10.88
52 WEEK LOW
3.380
MARKET CAP
1.35B
P/E (TTM)
-24.8528
1D
5D
1M
3M
1Y
5Y
We Think Shareholders Are Less Likely To Approve A Pay Rise For ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO For Now
The underwhelming share price performance of ImmunoGen, Inc. ( NASDAQ:IMGN ) in the past three years would have...
Simply Wall St. · 06/10 06:09
Immunogen Insights: Return On Capital Employed
Immunogen (NASDAQ:IMGN) reported Q1 sales of $15.71 million. Earnings fell to a loss of $28.92 million, resulting in a 179.18% decrease from last quarter. Immunogen earned $36.52 million, and sales totaled $85.80 million in Q4.
Benzinga · 06/07 14:00
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 28, 2021 the compensation committee of the Company's Board of Directors granted non-qualified stock o...
Business Wire · 06/01 20:30
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Benzinga · 05/31 15:06
Novel Anti-Cancer Drugs Permeate the Marketplace
, /PRNewswire/ -- The cancer therapeutics market is one of the largest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in in 2020 alone. However, the oncology and c...
PR Newswire - PRF · 05/25 13:00
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
Business Wire · 05/20 20:30
Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021
Cullinan Oncology (CGEM) - https://www.globenewswire.com/news-release/2021/05/19/2232874/0/en/Cullinan-Oncology-to-Provide-CLN-081-Clinical-Update-at-ASCO-2021.html BeiGene (BGNE)
Cullinan Oncology (CGEM) -  BeiGene (BGNE) · 05/19 21:25
BRIEF-Immunogen Announces Mature Data From Forward II Study Evaluating Mirvetuximab Soravtansine In Combination With Avastin In Recurrent Ovarian Cancer
reuters.com · 05/19 21:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMGN. Analyze the recent business situations of ImmunoGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMGN stock price target is 9.93 with a high estimate of 17.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 325
Institutional Holdings: 192.57M
% Owned: 96.31%
Shares Outstanding: 199.94M
TypeInstitutionsShares
Increased
72
20.71M
New
32
5.14M
Decreased
69
15.61M
Sold Out
26
1.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.68%
Pharmaceuticals & Medical Research
+1.50%
Key Executives
Chairman/Director
Stephen McCluski
Non-Executive Chairman/Independent Director
Stephen Mccluski
President/Chief Executive Officer/Director
Mark Enyedy
Chief Financial Officer/Senior Vice President
Susan Altschuller
Senior Vice President
Anna Berkenblit
Senior Vice President
Stacy Coen
Senior Vice President
Thomas Ryll
Senior Vice President
Theresa Wingrove
Independent Director
Stuart Arbuckle
Independent Director
Mark Goldberg
Independent Director
Dean Mitchell
Independent Director
Kristine Peterson
Independent Director
Richard Wallace
No Data
About IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.